Akari TherapeuticsNASDAQ: AKTX

Samir R. Patel, M.D. Appointed Interim CEO; Interim CEO Employment Contract Demonstrates Alignment with Shareholders

Pre-IND meeting with FDA completed with positive feedback on clinical and nonclinical development plans for PAS-nomacopan in treatment of geographic atrophy Pre-IND meeting with FDA completed with positive feedback on clinical and nonclinical development plans for PAS-nomacopan in treatment of geographic atrophy

Agreed to merge with Peak Bio in a definitive agreement, anticipated to be finalized in the third quarter of 2024.

Akari Therapeutics, Plc will be presenting new pre-clinical data on investigational long-acting PAS-nomacopan, including its effect on electroretinography (ERG) testing in a blue light model, at the upcoming ARVO 2024 Annual Meeting in Seattle. Chief Scientific Officer Miles Nunn will provide an overview of the data in a poster presentation on Sunday, May 5 from 1:00 to 2:45 pm PT.

NEW YORK and BOSTON, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that President and CEO Rachelle Jacques will present a company overview for in-person and virtual attendees at Biotech Showcase taking place in San Francisco, CA January 8-10, 2024, adjacent to the J.P. Morgan Healthcare Conference 2024. Akari management will attend one-on-one meetings during the conferences.

BOSTON and LONDON, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that the company will participate in the Emerging Growth Conference being held October 4 and 5, 2023. President and CEO Rachelle Jacques will present an overview of the company and its lead asset nomacopan, a bispecific inhibitor of complement C5 and leukotriene B4 (LTB4), on October 4, 2023 from 11:25 am to 11:55 am ET.

Penny stocks hold a distinctive charm for many investors. Amidst fluctuating market trends and the occasional downturn, there's often a group of these low-cost stocks surging in value.